Linzhi HEC Pharmaceutical Research

HEC Pharm, primarily operating through its research arm Sunshine Lake Pharma and its commercial entity YiChang HEC ChangJiang Pharmaceutical, is a leading Chinese pharmaceutical group focused on innovative drug discovery and high-end generic manufacturing. The company has established a dominant position in the Chinese antiviral market, most notably with its oseltamivir franchise (Kewei) and the development of the domestic NS5A inhibitor yimitasvir for Hepatitis C. HEC Pharm maintains an extensive R&D pipeline targeting metabolic disorders, oncology, and respiratory diseases, supported by large-scale manufacturing facilities that meet international GMP standards. The organization is characterized by its vertical integration, spanning from early-stage research to global commercial distribution.